To print: Select File and then Print from your browser's menu --------------------------------------------------------------------------------------- Title: Sleep Problems in Children With ADHD Not Linked to Methylphenidate: Presented at AACAP URL: http://www.pslgroup.com/dg/21690A.htm Doctor's Guide November 1, 2007
By Maria Bishop BOSTON, MA -- November 1, 2007 -- No significant effect of methylphenidate transdermal or oral formulation was observed on sleep problems in children taking the drug for attention-deficit hyperactivity disorder (ADHD), according to research presented here at the 54th Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP). Lead author Stephen V. Faraone, PhD, Director, Child and Adolescent Psychiatry Research, State University of New York Upstate Medical University, Syracuse, New York, United States stated that sleep problems are listed as common adverse effects of methylphenidate, but they have not been uniformly observed in clinical trials. In his study, following screening and a washout phase, 282 children aged 6 to 12 diagnosed with ADHD were randomised to methylphenidate transdermal (n = 100), methylphenidate oral (n = 94) or placebo (n = 88). At baseline and every week throughout the study, parents/caregivers assessed sleep behaviour in the children on the Children's Sleep Habits Questionnaire (CSHQ), a 33-item questionnaire. Subjects in the methylphenidate transdermal group received 10-mg, 15-mg, 20-mg and 30-mg patches; subjects in the oral group received doses of 18, 27, 36 and 53 mg. Titration upward was permitted after the subject had used the previous dose for at least 1 week. Tapering to a lower dose was permitted once. After 5 weeks, among the methylphenidate transdermal, methylphenidate oral or placebo groups, there was no significant difference in the severity of sleep problems: CSHQ mean total scores were 45.7, 45.9 and 46.7, respectively. Dr. Faraone noted that, with both methylphenidate formulations, baseline sleep scores predicted endpoint scores (P <.001). This study was not powered to compare the two formulations of methylphenidate. Funding was provided by Shire Development Inc. [Presentation title: Analysis of Sleep Effects in Children Treated With Once-Daily Methylphenidate: Abstract B30] --------------------------------------------------------------------------------------------- Copyright © 1999 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content. --------------------------------------------------------------------------------------------- This news story was printed from *Doctor's Guide to the Internet* located at http://www.docguide.com --------------------------------------------------------------------------------------- Return to News Story Page This site is maintained by webmaster@pslgroup.com Please contact us with any comments, problems or bugs. All contents Copyright (c) 1998 P\S\L Consulting Group Inc. All rights reserved.